Description

This product is a clear liquid, colorless to slightly yellow; it easily deteriorates when exposed to light.

Pharmacological Action

Pharmacodynamics：This product has good antibacterial activity against both Gram‑positive and Gram‑negative bacteria such as Streptococcus pyogenes, Salmonella spp., and Klebsiella pneumoniae. Sulfonamides are structurally similar to para‑aminobenzoic acid (PABA) and can compete with PABA for the bacterial enzyme dihydropteroate synthase, thereby inhibiting the synthesis of dihydrofolic acid, ultimately affecting nucleic acid synthesis and suppressing bacterial growth and reproduction. The action of sulfonamides can be antagonized by PABA and its derivatives (procaine, tetracaine). In addition, pus and tissue breakdown products can provide essential nutrients for bacterial growth, producing an antagonistic effect against sulfonamides. The antibacterial effect of this product is slightly weaker than that of sulfadiazine, but it has good inhibitory activity against coccidia and Toxoplasma gondii.

Pharmacokinetics：The pharmacokinetic characteristics of this product are basically similar to those of sulfadiazine. However, it has a higher plasma protein binding rate, so its excretion is slower than that of sulfadiazine. After oral administration, it is rapidly and completely absorbed, but excreted slowly, resulting in a longer duration of effective blood concentrations. Because its acetylated metabolite has high solubility, the incidence of crystal formation in the renal tubules is low, and it is less likely to cause crystalluria or hematuria. The elimination half‑life is 10.7–12.9 hours in yellow cattle and horses, 15.3 hours in pigs, and 4.7–5.8 hours in dairy goats and water buffalo.

Action and Use

Sulfonamide antibacterial agent. It is used for infections caused by susceptible bacteria and also for Toxoplasma gondii infections.

Dosage and Administration

Intravenous injection: single dose, per 1 kg body weight, domestic animals, 0.5–1 ml. Administer once or twice daily for 2–3 consecutive days.

Adverse Reactions

(1) Sulfonamides or their metabolites may precipitate in the urine, especially at high doses or during prolonged administration, leading to crystalluria, hematuria, or blockage of renal tubules.

(2) Intravenous injection in horses may cause transient paralysis.

(3) This product is a strongly alkaline solution and is highly irritating to tissues.

Precautions

(1) During treatment with sulfonamides, animals should be provided with plenty of water to prevent crystalluria; if necessary, alkaline agents such as sodium bicarbonate may also be administered orally.

(2) Use with caution in animals with impaired renal function, as excretion is slowed.

(3) This product may precipitate when mixed with acids, therefore it should not be diluted with 5% glucose solution.

(4) Be aware of cross‑allergic reactions. If allergic reactions or other serious adverse effects occur, discontinue administration immediately and provide symptomatic treatment.

Withdrawal Period

Withdrawal period: domestic animals 28 days; milk discard period 7 days.

Specification

(1) 5 ml : 0.5 g

(2) 10 ml : 1 g

(3) 100 ml : 10 g